NTRA Stock Price, Chart, Stats & News

Natera, Inc.
Save
33.62B
Market cap
–
Current P/E
–
Forward P/E
NTRA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 64.85% |
Operating margin | -13.44% |
Pretax margin | -11.63% |
Net margin | -9.03% |
Effective tax rate | 22.35% |
ROA | -8.30% |
ROE | -15.28% |
D/E | 0.13x |
Interest coverage ratio | -30.30x |
NTRA valuation
P/E | – |
P/S | 11.23x |
P/B | 14.58x |
P/CF | 115.99x |
P/FCF | 267.95x |
P/OCF | 115.99x |
PEG | -3.61x |
EV multiple | -103.73x |
About
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations.
Similar securities
Based on sector and market capitalization
Report issue











